Non-squamous Non-small Cell Lung Cancer Clinical Trial
Official title:
Phase II Trial of Bevacizumab and Ixabepilone for Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Progressive After First-line Therapy
Verified date | September 2015 |
Source | Providence Health & Services |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Interventional |
This is a non-randomized, open-label, single arm phase II trial of the combination of bevacizumab and ixabepilone in patients with advanced- or metastatic non-squamous NSCLC progressive after first or second-line therapy. The main objective is to evaluate the progression-free survival in patients with advanced or metastatic non-squamous NSCLC being treated with ixabepilone and bevacizumab.
Status | Terminated |
Enrollment | 6 |
Est. completion date | December 2013 |
Est. primary completion date | December 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Histologic or cytologic diagnosis of advanced or metastatic non-small cell lung cancer (NSCLC), excluding squamous cell-predominant subtype. NSCLC NOS (not otherwise specified) are eligible. - Patients must have had at least one but no more than two prior systemic chemotherapeutic regimens for metastatic disease. Prior neoadjuvant or adjuvant chemotherapy will not be included in the assessment as a prior chemotherapeutic regimen. Prior therapy with taxanes is allowed. Prior therapy with bevacizumab is allowed. - Prior chemotherapy or therapy with investigational agents must have been completed at least 3 weeks prior to study enrollment. - Zubrod performance status of 0 or 1. - Patients must have measurable or evaluable disease as defined by RECIST. - Treated brain metastases will be allowed, provided they are asymptomatic. Radiation treatment for brain metastasis must have been completed at least 2 weeks prior to enrollment. Patients must demonstrate stable symptoms and seizure control on a consistent dose of anticonvulsants for at least 2 weeks prior to enrollment. Patients must be off corticosteroids for at least 2 weeks. Treatment for brain metastases may include whole brain radiotherapy (WBRT), radiosurgery (RS; Gamma Knife, KINAC, or equivalent) or a combination as deemed appropriate by the treating physician. Patients with CNS metastases treated by neurosurgical resection or brain biopsy performed within 3 months prior to Day 1 will be excluded. - Radiation for symptomatic lesions outside the CNS must have been completed at least 2 weeks prior to study enrollment. If measurable disease is within the radiation field, there must be evidence of clear progression (using RECIST criteria) at the time of study enrollment. - Major surgical procedures must have been performed >28 days prior to study treatment. Portacath placement must have been performed >14 days prior to study treatment. Minor surgical procedures (fine needle aspiration, core biopsy, or mediastinoscopy) must have been performed >7 days prior to study treatment. - Patients must have normal organ and marrow function as defined below: - leukocytes > 3,000/uL - absolute neutrophil count > 1,500/uL - platelets > 100,000/uL - total bilirubin within normal institutional limits - AST (SGOT)/ALT (SGPT) < 2.5 X institutional upper limit of normal - creatinine < 1.5 mg/dL, OR - calculated creatinine clearance > 40 mL/min - Estimated life expectancy of greater than 12 weeks. - Patients must be able to sign informed consent. - Patients must be >18 years of age. Both men and women and members of all races and ethnic groups will be included. - Patients must either not be of child bearing potential or, if female, have a negative serum pregnancy test within 72 hours prior to Day 1. Patients are considered not of child bearing potential if they are surgically sterile (they have undergone a vasectomy, hysterectomy, bilateral tubal ligation, bilateral oophorectomy) or they are postmenopausal with no menses for at least 12 months. Patients of childbearing potential must be willing to use adequate barrier contraception for the duration of study participation and at least 30 days after study completion. Exclusion Criteria: - NSCLC with predominant squamous cell histology (mixed tumors will be categorized by the predominant cell type unless small cell elements are present, in which case the patient is ineligible; sputum cytology alone is not acceptable). - History of hemoptysis (bright red blood of 1/2 teaspoon or more per episode) within 1 month prior to Day 1. - Known CNS disease, except for treated brain metastasis. Treated brain metastases are defined as having no evidence of progression or hemorrhage after treatment and no ongoing requirement for dexamethasone (within the last two weeks prior to Day 1), as ascertained by clinical examination and brain imaging (MRI or CT) during the screening period. Anticonvulsants (stable dose) are allowed. Treatment for brain metastases may include whole brain radiotherapy (WBRT), radiosurgery (RS; Gamma Knife, LINAC, or equivalent) or a combination as deemed appropriate by the treating physician. Patients with CNS metastases treated by neurosurgical resection or brain biopsy performed within 3 months prior to Day 1 will be excluded. - Inability to comply with study and/or follow-up procedures. - An investigational agent within 3 weeks of Day 1. - Patients with greater than grade 1 neuropathy. - Pregnant (positive pregnancy test) or lactating. - Serious concomitant medical disorder, including active infection. - Active second primary malignancy at the time of study enrollment. - History of allergic reactions attributed to compounds of similar chemical or biologic composition to ixabepilone or Cremophor EL (polyoxyethylated castor oil). - History of co-existing psychiatric illness that could impair compliance with study protocol. - Inadequately controlled hypertension (defined as systolic blood pressure >150 and/or diastolic blood pressure > 100 mmHg on antihypertensive medications). - Any prior history of hypertensive crisis or hypertensive encephalopathy. - New York Heart Association (NYHA) Grade II or greater congestive heart failure. - History of myocardial infarction or unstable angina within 6 months prior to Day 1. - History of stroke or transient ischemic attack within 6 months prior to Day 1 of treatment. - Significant vascular disease (e.g., aortic aneurysm, aortic dissection). - Symptomatic peripheral vascular disease. - Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation). - Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 1 or anticipation of need for major surgical procedure during the course of the study. - Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to Day 1. - Portacath placement within 14 days prior to Day 1. - History of abdominal fistula or gastrointestinal perforation within 6 months prior to Day 1. - Serious, non-healing wound, active ulcer, or untreated bone fracture. - Proteinuria at screening as demonstrated by either: - Urine protein: creatinine (UPC) ratio = 1.0 at screening OR - Urine dipstick for proteinuria = 2+ (patients discovered to have =2+ proteinuria on dipstick urinalysis at screening should undergo a 24 hour urine collection and must demonstrate = 500 mg of protein in 24 hours to be eligible). - Known hypersensitivity to any component of bevacizumab. - Prior discontinuation of bevacizumab due to treatment-related toxicity. |
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Providence Portland Medical Center | Portland | Oregon |
Lead Sponsor | Collaborator |
---|---|
Providence Health & Services | Bristol-Myers Squibb, Genentech, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | progression-free survival | at week 8, week 16, and every 8 weeks until disease progression or removal from study | No | |
Secondary | To evaluate the overall response rate using RECIST criteria | at week 8, week 16, and every 8 weeks until disease progression or removal from study | No | |
Secondary | toxicities associated with treatment combination in advanced non-squamous NSCLC | all treatment days and every 2 months post-treatment | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02264990 -
Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Adults Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers
|
Phase 3 | |
Completed |
NCT01328951 -
A Study of First-line Maintenance Erlotinib Versus Erlotinib at Disease Progression in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Platinum-Based Chemotherapy
|
Phase 3 | |
Completed |
NCT01664533 -
An Observational Study of Erlotinib (Tarceva) as Second-line Treatment in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer After Failure of Pemetrexed in First-line Therapy
|
N/A | |
Completed |
NCT00988936 -
Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
|
Phase 2 | |
Completed |
NCT00976456 -
Efficacy Study of Avastin® With Pemetrexed +/- Carboplatin to Treat Elderly Patients With Non-small Cell Lung Cancer
|
Phase 3 | |
Completed |
NCT02596958 -
Safety and Efficacy Study of Avastin in Locally Advanced Metastatic or Recurrent Non-small Lung Cancer (NSLC) Participants
|
N/A | |
Completed |
NCT00974584 -
A Study of the Safety and Pharmacology Of PI3-Kinase Inhibitor GDC-0941 In Combination With Either Paclitaxel And Carboplatin (With or Without Bevacizumab) or Pemetrexed, Cisplatin, And Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer
|
Phase 1 | |
Completed |
NCT00451906 -
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
|
Phase 4 | |
Completed |
NCT03329911 -
A Comparative Study of BAT1706 and EU Avastin® in Patients With Advanced Non Squamous Non Small Cell Lung Cancer
|
Phase 3 | |
Not yet recruiting |
NCT03671538 -
Non Squamous NSCLC Patients With Anlotinib Combined With Pemetrexed and Cisplatin
|
N/A | |
Completed |
NCT01512420 -
An Observational Study of Tarceva (Erlotinib) in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer With Wild-Type Epidermal Growth Factor Receptor (EGFR) Gene (WILT)
|
N/A | |
Completed |
NCT01204697 -
A Study of Erlotinib [Tarceva] as Monotherapy or Intermittent Dosing With Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer. (TALISMAN)
|
Phase 2 | |
Completed |
NCT01185847 -
A Study of RO5083945 in Combination With Chemotherapy Versus Chemotherapy Alone in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
|
Phase 2 | |
Terminated |
NCT00760929 -
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).
|
Phase 2 | |
Withdrawn |
NCT03319316 -
Combination of Durvalumab and Tremelimumab as Maintenance Treatment in Patients With Non Squamous and Squamous (NSCLC)
|
Phase 2 | |
Recruiting |
NCT06334757 -
Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment Failure
|
Phase 2 | |
Recruiting |
NCT06396065 -
Phase III Study of AK112 for NSCLC Patients
|
Phase 3 | |
Completed |
NCT01174563 -
A Study on the Correlation Between Tarceva (Erlotinib) - Induced Rash and Efficacy in EGFR Mutated Participants With Advanced Non-Small Cell Lung Cancer Receiving First-Line Therapy
|
Phase 2 | |
Completed |
NCT01836133 -
An Observational Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Adenocarcinoma Non-Small Cell Lung Cancer (ELEMENT)
|
N/A | |
Terminated |
NCT01990261 -
A Study to Assess the Survival of Non-small Cell Lung Cancer Patients Treated With Tarceva After Failed Chemotherapy Treatment.
|
N/A |